Mozart Therapeutics racks up $55m Series A

Mozart Therapeutics Inc, a biopharmaceutical company focused on treating autoimmune and inflammatory disease, has raised $55 million in Series A financing.

Mozart Therapeutics Inc, a biopharmaceutical company focused on treating autoimmune and inflammatory disease, has raised $55 million in Series A financing. ARCH Venture Partners and Sofinnova Partners led the round with participation from other backers that include Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments.

Source: Press Release